Clinical trial · Observational
Quality of Life in Head and Neck Patients
Quality of Life Assessment Study in Patients With Metastatic Head and Neck Neoplasia Submitted to Immunotherapy in Brazil
NCT04853862CI-TRIAL-00051388QLiHNunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of health-related quality of life of head and neck cancer patients undergoing immunotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| questionnaire | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Quality of life
- timeFrame
- 2 years
- description
- Evaluation of quality of life based on validated questionnaire
- measure
- Overall survival
- timeFrame
- 2 years
- description
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients with a diagnosis of recurrent or metastatic squamous cell carcinoma of the head and neck region, whose planned treatment is immunotherapy, will be included. We will consider, separately, patients that had been treated with platinum before (platinum-refractory) and patients that were not submitted to this treatment (platinum naïve). Primary site: patients with primary pharyngeal tumors (oro or hypopharynx), oral cavity and larynx will be included. Exclusion Criteria: * Patients with cognitive impairment that prevents the proper application of questionnaires * Brain metastasis * Autoimmune disease * Systemic immunosuppressive treatment * Hepatitis B, C or HIV infection * Prior immunotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.